Opendata, web and dolomites

Wirecath SIGNED

Novel Catheter for the Diagnosis of Cardiovascular Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Wirecath project word cloud

Explore the words cloud of the Wirecath project. It provides you a very rough idea of what is the project "Wirecath" about.

clinical    optimises    breath    treatment    grants    effectiveness    innovation    plans    bases    group    validate    good    superior    evaluation    strategic    cad    trust    obstructive    premium    shortness    standard    intends    providers    plan    disease    medical    opportunity    healthcare    offers    accuracy    clinically    severity    pressure    solutions    million    substantially    misdiagnosis    patient    heart    technologies    patients    instrument    2019    benefits    sensor    wires    competing    assessing    diagnostic    sme    error    device    position    commercial    resistance    government    burden    deaths    complications    cardiologists    manoeuvrability    liable    reduce    attack    budgets    launch    wirecath    tools    man    angina    coronary    death    prevention    severe    narrowings    myocardial    first    commercialise    lasting    arteries    cavis    shareholders    cardiovascular    investment    progression    perform    artery    follow    diseases    hydrostatic    diagnosis    considerable    place    applicable    leads   

Project "Wirecath" data sheet

The following table provides information about the project.

Coordinator
CAVIS TECHNOLOGIES AB 

Organization address
address: KUNGSANGSVAGEN 29A 3TR
city: UPPSALA
postcode: 753 23
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CAVIS TECHNOLOGIES AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substantially reduce management costs in cardiovascular disease by improving its diagnosis, and thus, increasing opportunity for timely prevention of disease progression and its severe complications, such as angina, shortness of breath and heart attack. Wirecath has several premium features over competing solutions. These are an unique high accuracy, superior manoeuvrability and cost-effectiveness. Its simple and robust design bases on a unique position of pressure sensor and resistance to hydrostatic error, that standard pressure wires are liable to. Given that hydrostatic error often leads to misdiagnosis of the coronary artery disease severity, Wirecath optimises diagnostic accuracy and offers long-lasting benefits to patients, cardiologists and healthcare providers. The unique accuracy allow new methods to be developed, applicable to another large patient group that has non-obstructive CAD, with no good diagnosis tools available today. With this project, Cavis intends to support 2019’s commercial launch of Wirecath and plan further product development and large-scale clinical evaluation studies that will follow the first-in-man study planned for 2019. Cavis’ current research and development activities are supported by investment from shareholders and numerous innovation grants. Cavis plans to apply for SME Instrument Phase 2 funding to perform clinical studies that will build trust in its unique features and increase its commercial value. With 1.9 million deaths a year, cardiovascular diseases are the leading cause of death in the EU and place a considerable burden on healthcare systems and government budgets. Prevention and treatment of various cardiovascular diseases, is of a high strategic priority.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WIRECATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WIRECATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More